{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T05:15:10Z","timestamp":1778908510116,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.urolonc.2020.06.014","type":"journal-article","created":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T16:35:07Z","timestamp":1595090107000},"page":"850.e1-850.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?"],"prefix":"10.1016","volume":"38","author":[{"given":"Isamu","family":"Tachibana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elhaam","family":"Bandali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam C.","family":"Calaway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil","family":"Adra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hristos Z.","family":"Kaimakliotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.urolonc.2020.06.014_bib0001","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2020.06.014_bib0002","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.juro.2013.10.142","article-title":"Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate","volume":"191","author":"Lavery","year":"2014","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.014_bib0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-5347(05)67975-X","article-title":"Multivariate analysis of the prognostic factors of primary superficial bladder cancer","volume":"163","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.014_bib0004","doi-asserted-by":"crossref","first-page":"48","DOI":"10.6004\/jnccn.2009.0004","article-title":"Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis","volume":"7","author":"Nese","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.014_bib0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","article-title":"Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology","volume":"55","author":"Shabsigh","year":"2009","journal-title":"Eur Urol"},{"issue":"34","key":"10.1016\/j.urolonc.2020.06.014_bib0006","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.06.014_bib0007","unstructured":"Kassouf, W., A phase II trial of transurethral surgery followed by a combination of atezolizumab (Tecentriq\u2122) an anti-PDL-1 (MPDL3280A) with trimodal therapy in patients with muscle-invasive bladder cancer. 2018."},{"issue":"3","key":"10.1016\/j.urolonc.2020.06.014_bib0008","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0360-3016(03)00718-1","article-title":"RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy","volume":"57","author":"Hagan","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.urolonc.2020.06.014_bib0009","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1634\/theoncologist.5-6-471","volume":"5","author":"Kaufman","year":"2000","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.urolonc.2020.06.014_bib0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.urology.2008.09.036","article-title":"Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy","volume":"73","author":"Kaufman","year":"2009","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.urolonc.2020.06.014_bib0011","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","volume":"14","author":"Mitin","year":"2013","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2020.06.014_bib0012","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.014_bib0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.1996.14.1.119","article-title":"Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802","volume":"14","author":"Tester","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.06.014_bib0014","first-page":"viii726","article-title":"A phase Ib\/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)","volume":"29","author":"Hoimes","year":"2018","journal-title":"Ann Oncol 2018"},{"issue":"6","key":"10.1016\/j.urolonc.2020.06.014_bib0015","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.06.014_bib0016","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0022-5347(17)58916-8","article-title":"Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ","volume":"116","author":"Althausen","year":"1976","journal-title":"J Urol"},{"issue":"7 PT 2","key":"10.1016\/j.urolonc.2020.06.014_bib0017","first-page":"2495","article-title":"Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy","volume":"36","author":"Farrow","year":"1976","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.urolonc.2020.06.014_bib0018","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.014_bib0019","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/1097-0142(19940701)74:1<115::AID-CNCR2820740120>3.0.CO;2-R","article-title":"Carcinoma in situ of the urinary bladder. Clues to host involvement in human carcinogenesis.","volume":"74","author":"Orozco","year":"1994","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2020.06.014_bib0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.clgc.2016.11.009","article-title":"Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy","volume":"15","author":"Thomas","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2020.06.014_bib0021","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.juro.2014.11.003","article-title":"The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival","volume":"193","author":"Parker","year":"2015","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.06.014_bib0022","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0090-4295(01)01219-5","article-title":"Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder","volume":"58","author":"Zietman","year":"2001","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.urolonc.2020.06.014_bib0023","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.urolonc.2018.04.013","article-title":"Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry","volume":"36","author":"Daneshmand","year":"2018","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.06.014_bib0024","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41585-019-0184-4","article-title":"Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018","volume":"16","author":"Lotan","year":"2019","journal-title":"Nat Rev Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920302829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920302829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:19:01Z","timestamp":1761041941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920302829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1078143920302829"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.014","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}